PT - JOURNAL ARTICLE AU - Johannes Just AU - Marie-Therese Puth AU - Felix Regenold AU - Klaus Weckbecker AU - Markus Bleckwenn TI - Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results AID - 10.1101/2020.04.27.20081877 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.27.20081877 4099 - http://medrxiv.org/content/early/2020/07/30/2020.04.27.20081877.short 4100 - http://medrxiv.org/content/early/2020/07/30/2020.04.27.20081877.full AB - Background Combating the COVID-19 pandemic is a major challenge for health systems, citizens and policy makers worldwide. Early detection of affected patients within the large and heterogeneous group of patients with common cold symptoms is an important element of this effort, but often hindered by limited testing resources and the lack of pathognomonic symptoms in COVID-19. Therefore, we aimed to identify predictive risk factors for a positive SARS-CoV-2 PCR (CovPCR) result in a primary care setting.Method We performed a multi-center cross-sectional cohort study on predictive clinical characteristics for a positive CovPCR over a period of 4 weeks in primary care patients in Germany.Findings In total, 374 patients in 14 primary care centers received CovPCR and were included in this analysis. The median age was 44.0 (IQR: 31.0-59.0) and a fraction of 10.7% (n=40) tested positive for COVID-19. Patients who reported anosmia had a higher odds ratio (OR: 4.54; 95%-CI: 1.51-13.67) for a positive test result while patients with a sore throat had a lower OR (OR: 0.33; 95%-CI: 0.11-0.97). Patients who had a first grade contact with an infected persons and showed symptoms themselves also had an increased OR for positive testing (OR: 5.16; 95% CI: 1.72-15.51). This correlation was also present when they themselves were still asymptomatic (OR: 12.55; 95% CI: 3.97-39.67).Conclusions Several anamnestic criteria may be helpful to assess pre-test probability of COVID-19 in patients with common cold symptomsCompeting Interest StatementJJ, MP, KW and MB declare no competing interest. FR holds shares <5% of a regulatory affairs service company (Dr. Regenold GmbH)Funding StatementThis study was conducted without external financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study design was reviewed by the ethics committee of the University of Leipzig, Germany under the procedure number 184/20-ek, there were no ethical concerns.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the authors upon request within the framework of the basic data protection regulationCovPCRSARS-CoV-2 PCRPPVpositive-predictive value